SPRO - Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 25, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to two n

• 
  Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

  GlobeNewswire
• 
  Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer

  GlobeNewswire

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr program expected mid-year 2023; initiation of Phase 3 trial in complicated urinary tract infection (cUTI) expected in 2H 2023 Conference call and webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stag

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an u

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Spero’s management team will present and be available for one-on-one meetings at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity investment, and eligibility for future milestone payments and tiered royalties Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a mu

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, Monday, March 13, 2023 to

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and

Spero Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43r

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one me

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of common stock, with potential for future milestone payments and tiered royalties Initiation of a placebo-controlled Phase 2 trial designed to provide clinical proof-of-concept for SPR720 in nontuberculous mycobacterial pulmonary disease with top line results expected in 1H 2024 Conference call and live we

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royaltiesCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide

Spero Therapeutics to Present Data at IDWeek 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced data presentations for 7 abstracts accepted at the Infectious Disease Society of America (IDSA) IDWeek™ 2022, taking place from October 19 – 23, 2022 in Washington, DC

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School) CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bac

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agree

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective productsCAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises,” said Ankit Mahadevia, MD, Chief Executive Officer o

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients with complicated urinary tract infection (cUTI), with supportive confirmatory evidence of efficacy could support approval of tebipenem HBr Spero plans to advance tebipenem HBr’s clinical development and potential commercialization through external partnership CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE N

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen Trial of SPR206 Expected in 3Q 2023 Continued Engagement with FDA is Expected to Provide Key Insights into the Path Forward for Tebipenem HBr Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announc

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565. The audio webcast can be accessed under “Events and Pr

Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis. The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022. In th